$PAND News
Last published 5y ago
- 5y agoMRKPANDMerck Completes Acquisition of Pandion TherapeuticsBusiness WireKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Pandion Therapeutics, Inc. (Nasdaq: PAND) at a purchase price of $60 per share. As of the tender offer expiration, 27,770,123 shares of common stock of ...
- 5y agoMRKPANDMerck Begins Tender Offer to Acquire Pandion TherapeuticsBusiness WireKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Pandion Therapeutics, Inc. (Nasdaq: PAND). On Feb. 25, 2021, Merck announced its intent to acquire Pandion.
- 5y agoRTPPRAHSFTWPANDMoore Kuehn Encourages SFTW, PRAH, RTP, and PAND Investors to Contact Law FirmGlobeNewswireNEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
- 5y agoPANDMerck to Buy Autoimmune Drug Developer Pandion for $1.85 BillionBloombergMerck & Co. agreed to acquire Pandion Therapeutics Inc., a biotechnology company developing therapies for autoimmune diseases, for $1.85 billion.
- 5y agoMRKPANDMerck to Acquire Pandion TherapeuticsBusiness WireKENILWORTH, N.J & WATERTOWN, Mass.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pandion Therapeutics, Inc. (Nasdaq: PAND) today announced that the companies have entered into a definitive agreement, under which Merck, through a subsidiary, will acquire Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to address th ...
- 5y agoPANDPandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific MeetingGlobeNewswireWATERTOWN, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
- 5y agoPANDPandion Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireWATERTOWN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
- 5y agoPANDPandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cellsGlobeNewswire-Phase 1a trial achieved primary objective of safety and tolerability-PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in...
- 5y agoFULCPANDECOLNodThera Appoints Chief Medical Officer and Chief Financial OfficerBusiness WireCAMBRIDGE, England & BOSTON & SEATTLE--(BUSINESS WIRE)--NodThera, a biotechnology company developing a new class of medicines that inhibit the NLRP3 inflammasome to treat chronic inflammation, today announced the expansion of its senior leadership team with the appointments of Donald Johns, M.D., as Chief Medical Officer and Katina Dorton, J.D., MBA, as Chief Financial Officer.
- 5y agoPANDPandion Therapeutics Appoints Katina Dorton to its Board of DirectorsGlobeNewswireWATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
- 5y agoPANDPandion Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business UpdateGlobeNewswire- Enrollment and dosing complete in Phase 1a clinical trial of PT101; top-line results expected early 2021- PT627 systemic PD-1 agonist development candidate nominated; IND-enabling studies expected...
- 6y agoPANDPandion Therapeutics to Present at the Stifel 2020 Virtual Healthcare ConferenceGlobeNewswireWATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
- 6y agoPANDPandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 2020GlobeNewswireWATERTOWN, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
- 6y agoPANDPandion Therapeutics to Participate in Panel Discussion at Stifel 2020 Immunology & Inflammation Virtual SummitGlobeNewswireWATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
- 6y agoPANDPandion Therapeutics to Present at Morgan Stanley Global Healthcare ConferenceGlobeNewswireWATERTOWN, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
- 6y agoPANDPandion Reports Second Quarter 2020 Financial Results and Provides Business UpdateGlobeNewswire- Completed successful IPO providing approximately $153 million in gross proceeds; cash runway extended through first half of 2024 - Expanded executive team with appointment of John S. Sundy, M.D.,...
- 6y agoPANDPandion Therapeutics Announces Pricing of Initial Public OfferingGlobeNewswireWATERTOWN, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...